Maynard Um
-
-
-
-
-
-
-
AngioDynamics reports sustained prostate cancer treatment outcomes at 24 months
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on AngioDynamics (ANGO)
-
-
-
-
-
-
-
AngioDynamics (ANGO) PT Raised to $17 at Canaccord Genuity
-
-
-
-
-
-
-
AngioDynamics (ANGO) Announces Publication of APEX-AV Trial Results in JSCAI
-
-
-
-
-
-
-
AngioDynamics (ANGO) Tops Q1 EPS by 5c ; Offers Guidance
-
-
-
-
-
422,368 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

